230 related articles for article (PubMed ID: 27669438)
1. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
Lefort S; Thuleau A; Kieffer Y; Sirven P; Bieche I; Marangoni E; Vincent-Salomon A; Mechta-Grigoriou F
Oncogene; 2017 Mar; 36(9):1211-1222. PubMed ID: 27669438
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor RUNX2 up-regulates chemokine receptor CXCR4 to promote invasive and metastatic potentials of human gastric cancer.
Guo ZJ; Yang L; Qian F; Wang YX; Yu X; Ji CD; Cui W; Xiang DF; Zhang X; Zhang P; Wang JM; Cui YH; Bian XW
Oncotarget; 2016 Apr; 7(15):20999-1012. PubMed ID: 27007162
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Yang F; Takagaki Y; Yoshitomi Y; Ikeda T; Li J; Kitada M; Kumagai A; Kawakita E; Shi S; Kanasaki K; Koya D
Cancer Res; 2019 Feb; 79(4):735-746. PubMed ID: 30584072
[TBL] [Abstract][Full Text] [Related]
4. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.
Katkoori VR; Basson MD; Bond VC; Manne U; Bumpers HL
Oncotarget; 2015 Sep; 6(29):27763-77. PubMed ID: 26318034
[TBL] [Abstract][Full Text] [Related]
5. CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers.
Misra AC; Luker KE; Durmaz H; Luker GD; Lahann J
Biomacromolecules; 2015 Aug; 16(8):2412-7. PubMed ID: 26154069
[TBL] [Abstract][Full Text] [Related]
6. VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Pham K; Luo D; Siemann DW; Law BK; Reynolds BA; Hothi P; Foltz G; Harrison JK
Cancer Lett; 2015 Apr; 360(1):60-7. PubMed ID: 25676691
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis.
Martinez-Ordoñez A; Seoane S; Cabezas P; Eiro N; Sendon-Lago J; Macia M; Garcia-Caballero T; Gonzalez LO; Sanchez L; Vizoso F; Perez-Fernandez R
Oncogene; 2018 Mar; 37(11):1430-1444. PubMed ID: 29321662
[TBL] [Abstract][Full Text] [Related]
9. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
[TBL] [Abstract][Full Text] [Related]
10. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.
Conley-LaComb MK; Semaan L; Singareddy R; Li Y; Heath EI; Kim S; Cher ML; Chinni SR
Mol Cancer; 2016 Nov; 15(1):68. PubMed ID: 27809841
[TBL] [Abstract][Full Text] [Related]
12. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases.
Gil M; Seshadri M; Komorowski MP; Abrams SI; Kozbor D
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1291-300. PubMed ID: 23509246
[TBL] [Abstract][Full Text] [Related]
13. Krüppel-like factor 8 activates the transcription of C-X-C cytokine receptor type 4 to promote breast cancer cell invasion, transendothelial migration and metastasis.
Mukherjee D; Lu H; Yu L; He C; Lahiri SK; Li T; Zhao J
Oncotarget; 2016 Apr; 7(17):23552-68. PubMed ID: 26993780
[TBL] [Abstract][Full Text] [Related]
14. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.
Tamamura H; Hori A; Kanzaki N; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2003 Aug; 550(1-3):79-83. PubMed ID: 12935890
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of CXCR4 synergizes with LL-37 in the metastasis of breast cancer cells.
Pan WL; Wang Y; Hao Y; Wong JH; Chan WC; Wan DC; Ng TB
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3837-3846. PubMed ID: 30251699
[TBL] [Abstract][Full Text] [Related]
16. Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers.
Ananthula S; Sinha A; El Gassim M; Batth S; Marshall GD; Gardner LH; Shimizu Y; ElShamy WM
Oncotarget; 2016 Apr; 7(15):20869-89. PubMed ID: 26989079
[TBL] [Abstract][Full Text] [Related]
17. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
Benedicto A; Romayor I; Arteta B
Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
[TBL] [Abstract][Full Text] [Related]
18. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling.
Ping YF; Yao XH; Jiang JY; Zhao LT; Yu SC; Jiang T; Lin MC; Chen JH; Wang B; Zhang R; Cui YH; Qian C; Wang Jm; Bian XW
J Pathol; 2011 Jul; 224(3):344-54. PubMed ID: 21618540
[TBL] [Abstract][Full Text] [Related]
19. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation.
Zhou KX; Xie LH; Peng X; Guo QM; Wu QY; Wang WH; Zhang GL; Wu JF; Zhang GJ; Du CW
Cancer Lett; 2018 Apr; 418():196-203. PubMed ID: 29317253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
